T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies

• Published in: British journal of haematology Vol. 196; no. 3; pp. 548 - 558
• Main Authors: Marasco, Vincenzo, Carniti, Cristiana, Guidetti, Anna, Farina, Lucia, Magni, Martina, Miceli, Rosalba, Calabretta, Ludovica, Verderio, Paolo, Ljevar, Silva, Serpenti, Fabio, Morelli, Daniele, Apolone, Giovanni, Ippolito, Giuseppe, Agrati, Chiara, Corradini, Paolo
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.02.2022; John Wiley and Sons Inc
• Subjects: 2019-nCoV Vaccine mRNA-1273 - administration & dosage; 2019-nCoV Vaccine mRNA-1273 - immunology; Aged; Antibodies, Viral - immunology; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; anti‐CD20 antibody; BNT162 Vaccine - administration & dosage; BNT162 Vaccine - immunology; CD20 antigen; Chemotherapy; Chronic lymphocytic leukemia; COVID-19; COVID-19 - immunology; COVID-19 - prevention & control; Female; Hematologic Neoplasms - drug therapy; Hematologic Neoplasms - immunology; Hematology; Humans; Immune response; Immune response (cell-mediated); Immunity, Cellular - drug effects; Immunoglobulin M; Immunoglobulin M - immunology; lymphoid malignancies; Lymphoma; Lymphoproliferative Disorders - drug therapy; Lymphoproliferative Disorders - immunology; Male; Middle Aged; mRNA; Multiple myeloma; Multivariate analysis; Patients; Prospective Studies; Research Paper; SARS-CoV-2 - immunology; Seroconversion; Serology; Severe acute respiratory syndrome coronavirus 2; T-Lymphocytes - immunology; T‐cell immune response; COVID-19; Seroconversion; anti-CD20 antibody; lymphoid malignancies; T-cell immune response

Summary Patients affected by lymphoid malignancies (LM) are frequently immune‐compromised, suffering increased mortality from COVID‐19. This prospective study evaluated serological and T‐cell responses after complete mRNA vaccination in 263 patients affected by chronic lymphocytic leukaemia, B‐ and...